Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas.
Shah SB, Carlson CR, Lai K, Zhong Z, Marsico G, Lee KM, Félix Vélez NE, Abeles EB, Allam M, Hu T, Walter LD, Martin KE, Gandhi K, Butler SD, Puri R, McCleary-Wheeler AL, Tam W, Elemento O, Takata K, Steidl C, Scott DW, Fontan L, Ueno H, Cosgrove BD, Inghirami G, García AJ, Coskun AF, Koff JL, Melnick A, Singh A. Shah SB, et al. Nat Mater. 2023 Apr;22(4):511-523. doi: 10.1038/s41563-023-01495-3. Epub 2023 Mar 16. Nat Mater. 2023. PMID: 36928381 Free PMC article.
Multiscale engineering of immune cells and lymphoid organs.
Kim S, Shah SB, Graney PL, Singh A. Kim S, et al. Among authors: shah sb. Nat Rev Mater. 2019 Jun;4(6):355-378. doi: 10.1038/s41578-019-0100-9. Epub 2019 Apr 3. Nat Rev Mater. 2019. PMID: 31903226 Free PMC article.
How Biophysical Forces Regulate Human B Cell Lymphomas.
Apoorva F, Loiben AM, Shah SB, Purwada A, Fontan L, Goldstein R, Kirby BJ, Melnick AM, Cosgrove BD, Singh A. Apoorva F, et al. Among authors: shah sb. Cell Rep. 2018 Apr 10;23(2):499-511. doi: 10.1016/j.celrep.2018.03.069. Cell Rep. 2018. PMID: 29642007 Free PMC article.
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.
Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, Trujillo-Alonso V, Teater MR, van Besien H, Gibbs-Curtis D, Ueno H, Parvin S, Letai A, Mathew S, Singh A, Cesarman E, Melnick A, Giulino-Roth L. Scholze H, et al. Blood Adv. 2020 Oct 27;4(20):5226-5231. doi: 10.1182/bloodadvances.2020002580. Blood Adv. 2020. PMID: 33104794 Free PMC article.
334 results